Measure Name:
Renal Dysfunction: New Oral Anticoagulants (NOACs) Management
QCDR Measure ID:
CLLC7
QCDR Measure Type
New QCDR Measure
NQF ID Number (if applicable)
N/A
High Priority Type
Patient Safety
Measure Type
Process
NQS Domain
Patient Safety
Inverse Measure
No
Proportional Measure
Yes
Continuous Variable Measure
No
Ratio Measure
No
Number of performance rates to be calculated and submitted in the XML
1
Risk-Adjusted
No
If risk-adjusted, indicate which score is risk-adjusted
N/A
Measure Description:
The percentage of adult patients prescribed an ACEI, ARB, digoxin, diuretic, metformin, or NOACs who have had a serum creatinine measured in the past 12 months and who are on the appropriate dosage of NOACs based on renal function
What one meaningful measure area applies to this measure?
Preventable Healthcare Harm
Rational:
The medications included in this measure are known to impact renal function and/or their dosing is impacted by renal function. Routine monitoring of these commonly prescribed medications and narrow therapeutic index medications (e.g. digoxin) is recommended to prevent potential adverse drug events.
Denominator:
Patients 18 years of age and older with a current prescription for an ACEI, ARB, Digoxin, any diuretic (i.e., Thiazide, Loop, K Sparing, or Spironolactone), Metformin, or New Oral Anticoagulants (NOACs)
Denominator Exclusions:
Patients with Edoxaban Rx
Numerator:
Patients with a serum creatinine measured in past year who are on appropriate daily dose of NOACs according to renal function
Numerator Exclusions:
None
Denominator Exceptions:
None